Reference
Health Canada. Summary Safety Review - Pomalyst (pomalidomide) and Thalomid (thalidomide) - Assessing the Potential Risk of Progressive Multifocal Leukoencephalopathy. Internet Document : 27 May 2021. Available from: URL: https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&linkID=SSR00268
Rights and permissions
About this article
Cite this article
Health Canada warns of pomalidomide and thalidomide-related PML. Reactions Weekly 1859, 1 (2021). https://doi.org/10.1007/s40278-021-97097-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-97097-8